U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVES COMBINATION TREATMENT OF VENCLEXTA® (VENETOCLAX) AND ACALABRUTINIB FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.